Citation: | Yan Xijing, Yang Yang. Research progress on the application of liver transplantation in HIV combined with HCV positive patients[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005 |
[1] |
MORABITO V, GROSSI P, LOMBARDINI L, et al. Solid organ transplantation in HIV+ recipients: Italian experience[J]. Transplant Proc, 2016, 48(2):424-430. DOI: 10.1016/j.transproceed.2015.12.049.
|
[2] |
HIV in the United States and Dependent Areas[EB/OL].[2020-06-10]. https://www.cdc.gov/hiv/statistics/overview/ataglance.html.
|
[3] |
LOCKE JE, DURAND C, REED RD, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients[J]. Transplantation, 2016, 100(1):141-146. DOI: 10.1097/TP.0000000000000829.
|
[4] |
BLUMBERG EA, STOCK P, AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient[J]. Am J Transplant, 2009, 9 (Suppl 4):S131-S135. DOI: 10.1111/j.1600-6143.2009.02903.x.
|
[5] |
STOCK PG, ROLAND ME. Evolving clinical strategies for transplantation in the HIV-positive recipient[J]. Transplantation, 2007, 84(5):563-571. DOI: 10.1097/01.tp.0000279190.96029.77.
|
[6] |
LACOMBE K, ROCKSTROH J. HIV and viral hepatitis coinfections: advances and challenges[J]. Gut, 2012, 61(Suppl 1):i47-i58. DOI: 10.1136/gutjnl-2012-302062.
|
[7] |
WEBER R, SABIN CA, FRⅡS-MØLLER N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study[J]. Arch Intern Med, 2006, 166(15):1632-1641. DOI: 10.1001/archinte.166.15.1632.
|
[8] |
COOPER C, ROLLET-KURHAJEC KC, YOUNG J, et al. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients[J]. HIV Med, 2015, 16(1):24-31. DOI: 10.1111/hiv.12168.
|
[9] |
Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS statistics - 2020 fact sheet[EB/OL].[2020-05-05]. http://unaids.mio.guru/en/resources/fact-sheet.
|
[10] |
WERBEL WA, DURAND CM. Solid organ transplantation in HIV-infected recipients: history, progress, and frontiers[J]. Curr HIV/AIDS Rep, 2019, 16(3):191-203. DOI: 10.1007/s11904-019-00440-x.
|
[11] |
BACCARANI U, RIGHI E, ADANI GL, et al. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients[J]. World J Gastroenterol, 2014, 20(18):5353-5362. DOI: 10.3748/wjg.v20.i18.5353.
|
[12] |
MURILLAS J, RIMOLA A, LAGUNO M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study[J]. Liver Transpl, 2009, 15(9):1133-1141. DOI: 10.1002/lt.21735.
|
[13] |
VAN PILSUM RASMUSSEN SE, BOWRING MG, SHAFFER AA, et al. Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers[J]. Clin Transplant, 2018, 32(10):e13365. DOI: 10.1111/ctr.13365.
|
[14] |
CAMPOS-VARELA I, DODGE JL, BERENGUER M, et al. Temporal trends and outcomes in liver transplantation for recipients with HIV infection in Europe and United States[J]. Transplantation, 2020, 104(10):2078-2086. DOI: 10.1097/TP.0000000000003107.
|
[15] |
SORIANO V, PUOTI M, PETERS M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-hepatitis B virus international panel[J]. AIDS, 2008, 22(12):1399-1410. DOI: 10.1097/QAD.0b013e3282f8b46f.
|
[16] |
SULKOWSKI MS. Management of hepatic complications in HIV-infected persons[J]. J Infect Dis, 2008, 197(Suppl 3):S279-S293. DOI: 10.1086/533414.
|
[17] |
OCKENGA J, TILLMANN HL, TRAUTWEIN C, et al. Hepatitis B and C in HIV-infected patients. prevalence and prognostic value[J]. J Hepatol, 1997, 27(1):18-24. DOI: 10.1016/s0168-8278(97)80274-7.
|
[18] |
STAPLES CT JR, RIMLAND D, DUDAS D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival[J]. Clin Infect Dis, 1999, 29(1):150-154. DOI: 10.1086/520144.
|
[19] |
SORIANO V, GARCÍA-SAMANIEGO J, BRAVO R, et al. Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus[J]. Med Clin (Barc), 1995, 104(17):641-644. http://www.ncbi.nlm.nih.gov/pubmed/7623489
|
[20] |
BENHAMOU Y, BOCHET M, DI MARTINO V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. the multivirc group[J]. Hepatology, 1999, 30(4):1054-1058. DOI: 10.1002/hep.510300409.
|
[21] |
PINEDA JA, ROMERO-GÓMEZ M, DÍAZ-GARCÍA F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis[J]. Hepatology, 2005, 41(4):779-789. DOI: 10.1002/hep.20626.
|
[22] |
PINEDA JA, GARCÍA-GARCÍA JA, AGUILAR-GUISADO M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy[J]. Hepatology, 2007, 46(3):622-630. DOI: 10.1002/hep.21757.
|
[23] |
GARBA ML, PILCHER CD, BINGHAM AL, et al. HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells[J]. J Immunol, 2002, 168(5):2247-2254. DOI: 10.4049/jimmunol.168.5.2247.
|
[24] |
隋国德, 程广, 袁俊俊, 等. IL-13 PGE2 PGI2通过PKC通路活化肝星形细胞参与肝脏纤维化作用研究[J].现代医药卫生, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005.
SUI GD, CHENG G, YUAN JJ, et al. Role of IL-13, PGE2 and PGI2 for participating in hepatic fibrosis by activating hepatic stellate cells through PKC path-way[J]. J Mod Med Health, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005.
|
[25] |
王甘露, 邵圣文, 徐伯赢, 等.丙型肝炎病毒F蛋白上调肝星形细胞胶原表达[J].中国普外基础与临床杂志, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009
WANG GL, SHAO SW, XU BY, et al. Up-regulation of collagen expression in hepatic stellate cells by F protein of hepatitis C virus[J]. Chin J Base Clin General Sur, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009
|
[26] |
SAFADI R, OHTA M, ALVAREZ CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes[J]. Gastroenterology, 2004, 127(3):870-882. DOI: 10.1053/j.gastro.2004.04.062.
|
[27] |
王思奇.肝脏免疫微环境与肝纤维化的研究进展[J].复旦学报(医学版), 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021.
WANG SQ. Research progress in liver immune microenvironment and liver fibrosis[J]. Fudan Univ J Med Sci, 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021.
|
[28] |
WEN J, ZHOU Y, WANG J, et al. Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway[J]. Cell Death Differ, 2017, 24(6):997-1006. DOI: 10.1038/cdd.2017.31.
|
[29] |
HSU YC, LIN JT, HO HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients[J]. Hepatology, 2014, 59(4):1293-1302. DOI: 10.1002/hep.26892.
|
[30] |
CARVALHO RF, ATTA AM, DE OLIVEIRA IS, et al. Adiponectin levels and insulin resistance among patients with chronic hepatitis C[J]. Acta Trop, 2018, 178:258-263. DOI: 10.1016/j.actatropica.2017.12.004.
|
[31] |
BLANCO F, BARREIRO P, RYAN P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance[J].J Viral Hepat, 2011, 18(1):11-16. DOI: 10.1111/j.1365-2893.2009.01261.x.
|
[32] |
GANESAN M, POLUEKTOVA LY, KHARBANDA KK, et al. Liver as a target of human immunodeficiency virus infection[J]. World J Gastroenterol, 2018, 24(42):4728-4737. DOI: 10.3748/wjg.v24.i42.4728.
|
[33] |
MORENO A, CERVERA C, FORTÚN J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study[J]. Liver Transpl, 2012, 18(1):70-81. DOI: 10.1002/lt.22431.
|
[34] |
HONG F, SAIMAN Y, SI C, et al. X4 human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4[J]. PLoS One, 2012, 7(3):e33659. DOI: 10.1371/journal.pone.0033659.
|
[35] |
DAGUR RS, WANG W, CHENG Y, et al. Human hepatocyte depletion in the presence of HIV-1 infection in dual reconstituted humanized mice[J]. Biol Open, 2018, 7(2):bio029785. DOI: 10.1242/bio.029785.
|
[36] |
MUNSHI N, BALASUBRAMANIAN A, KOZIEL M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism[J]. J Infect Dis, 2003, 188(8):1192-1204. DOI: 10.1086/378643.
|
[37] |
JANG JY, SHAO RX, LIN W, et al. HIV infection increases HCV-induced hepatocyte apoptosis[J]. J Hepatol, 2011, 54(4):612-620. DOI: 10.1016/j.jhep.2010.07.042.
|
[38] |
BRUNO R, GALASTRI S, SACCHI P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis[J]. Gut, 2010, 59(4):513-520. DOI: 10.1136/gut.2008.163287.
|
[39] |
VALI B, YUE FY, JONES RB, et al. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection[J]. PLoS One, 2008, 3(10):e3454. DOI: 10.1371/journal.pone.0003454.
|
[40] |
SANDLER NG, DOUEK DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities[J]. Nat Rev Microbiol, 2012, 10(9):655-666. DOI: 10.1038/nrmicro2848.
|
[41] |
GE D, FELLAY J, THOMPSON AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262):399-401. DOI: 10.1038/nature08309.
|
[42] |
RALLÓN NI, NAGGIE S, BENITO JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients[J]. AIDS, 2010, 24(8):F23-F29. DOI: 10.1097/QAD.0b013e3283391d6d.
|
[43] |
MANZARDO C, LONDOÑO MC, CASTELLS L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study[J]. Am J Transplant, 2018, 18(10):2513-2522. DOI: 10.1111/ajt.14996.
|
[44] |
TANAKA T, AKAMATSU N, KANEKO J, et al. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection[J]. Hepatol Res, 2016, 46(8):829-832. DOI: 10.1111/hepr.12614.
|
[45] |
DUCLOS-VALLÉE JC, FÉRAY C, SEBAGH M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus[J]. Hepatology, 2008, 47(2):407-417. DOI: 10.1002/hep.21990.
|
[46] |
MIRO JM, MONTEJO M, CASTELLS L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study[J]. Am J Transplant, 2012, 12(7):1866-1876. DOI: 10.1111/j.1600-6143.2012.04028.x.
|
[47] |
TERRAULT NA, ROLAND ME, SCHIANO T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection[J]. Liver Transpl, 2012, 18(6):716-726. DOI: 10.1002/lt.23411.
|
[48] |
MIRO JM, STOCK P, TEICHER E, et al. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. a 2015 update[J]. J Hepatol, 2015, 62(3):701-711. DOI: 10.1016/j.jhep.2014.10.032.
|
[49] |
KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2):464-470. DOI: 10.1053/jhep.2001.22172.
|
[50] |
SULKOWSKI MS. Viral hepatitis and HIV coinfection[J]. J Hepatol, 2008, 48(2):353-367. DOI: 10.1016/j.jhep.2007.11.009.
|
[51] |
FERRARESE A, ZANETTO A, GAMBATO M, et al. Liver transplantation for viral hepatitis in 2015[J]. World J Gastroenterol, 2016, 22(4):1570-1581. DOI: 10.3748/wjg.v22.i4.1570.
|
[52] |
TE HS. Recurrent hepatitis C: the bane of transplant hepatology[J]. Hepatology, 2014, 59(1):21-23. DOI: 10.1002/hep.26591.
|
[53] |
BERENGUER M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin[J]. J Hepatol, 2008, 49(2):274-287. DOI: 10.1016/j.jhep.2008.05.002.
|
[54] |
DUCLOS-VALLEE JC, TATEO M, TEICHER E, et al. Results of liver transplantation in a large cohort of more than 100 HIV infected patients - a monocentric experience[J]. Hepatology, 2011, 54(suppl 4):361A. http://www.researchgate.net/publication/295927763_Results_of_Liver_Transplantation_in_a_Large_Cohort_of_More_Than_100_HIV_Infected_Patients_-_A_Monocentric_Experience
|
[55] |
TERRAULT N, REDDY KR, POORDAD F, et al. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients[J]. Am J Transplant, 2014, 14(5):1129-1135. DOI: 10.1111/ajt.12668.
|
[56] |
CASTELLS L, RIMOLA A, MANZARDO C, et al. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study[J]. J Hepatol, 2015, 62(1):92-100. DOI: 10.1016/j.jhep.2014.07.034.
|
[57] |
PELLICELLI AM, MONTALBANO M, LIONETTI R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late[J]. Dig Liver Dis, 2014, 46(10):923-927. DOI: 10.1016/j.dld.2014.06.004.
|
[58] |
ANTONINI TM, FURLAN V, TEICHER E, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation[J]. AIDS, 2015, 29(1):53-58. DOI: 10.1097/QAD.0000000000000516.
|
[59] |
李俊利, 尚佳, 宁会彬.直接抗病毒药物时代特殊人群HCV感染的管理和治疗[J].临床肝胆病杂志, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005.
LI JL, SHANG J, NING HB. Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005.
|
[60] |
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026.
|
[61] |
HOUSSEL-DEBRY P, COILLY A, FOUGEROU-LEURENT C, et al. 12 weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation[J]. Hepatology, 2018, 68(4):1277-1287. DOI: 10.1002/hep.29918.
|
[62] |
SALCEDO M, PRIETO M, CASTELLS L, et al. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. role of cirrhosis and genotype 3. a multicenter cohort study[J]. Transpl Int, 2017, 30(10):1041-1050. DOI: 10.1111/tri.12999.
|
[63] |
REAU N, KWO PY, RHEE S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection[J]. Hepatology, 2018, 68(4):1298-1307. DOI: 10.1002/hep.30046.
|
[64] |
CHEN JY, FEENEY ER, CHUNG RT. HCV and HIV co-infection: mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(6):362-371. DOI: 10.1038/nrgastro.2014.17.
|
[65] |
BULTEEL N, LEEN C. Editorial: direct-acting anti-virals-not the be-all and end-all in HIV/HCV co-infection[J]. Aliment Pharmacol Ther, 2017, 45(4):569-570. DOI: 10.1111/apt.13884.
|
[66] |
SCHLABE S, ROCKSTROH JK. Advances in the treatment of HIV/HCV coinfection in adults[J]. Expert Opin Pharmacother, 2018, 19(1):49-64. DOI: 10.1080/14656566.2017.1419185.
|
[67] |
李雯彬, 张文杰, 张晓瑛, 等.直接抗病毒药物时代下丙型病毒性肝炎的研究现状[J].中国中西医结合消化杂志, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X.2018.10.19.
LI WB, ZHANG WJ, ZHANG XY, et al. Research status of hepatitis C virus in the era of liver direct antiviral drugs[J]. Chin J Integr Trad West Med Dig, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X. 2018.10.19.
|